

loc 200153312 (in person)

ID AAM397el standard; Protein; 772 AA.
XX
A* AAM397el;
XX
DT 22-OCT-2001 (first entry)
XX
IE Human polypeptide SEQ ID NO: 2406.
XX
FW Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer;
FW peripheral nervous system; neuropathy; central nervous system; CNS;
FW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
FW amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
FW chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
FW leukaemia.
XX
OS Homo sapiens.
XX
DN W0200153312-A1.
XX
PD 26-JUL-2001.
XX
PF 26-DEC-2000; 2000WD-US84283.
XX
PF 21-JAN-2000; 2000US-0468725.
PF 25-APR-2000; 2000US-0512317.
PF 09-JUL-2000; 2000US-0528042.
PF 19-JUL-2000; 2000US-0510312.
PF 03-AUG-2000; 2000US-0613450.
PF 14-SEP-2000; 2000US-0662191.
PF 19-OCT-2000; 2000US-0683036.
PF 23-NOV-2000; 2000US-0727844.
XX
PA HYSE-) HYSEQ INC.
XX
FI Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;
FI Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J;
FI Zhao ZA, Zhou P, Goldrich E, Drmanac RT;
XX
DP WPI; 2001-442253/47.
DE N-PSDB; AAI58937.
XX
FT Novel nucleic acids and polypeptides, useful for treating disorders
FT such as central nervous system injuries -
XX
IS Example 4; SEQ ID NO: 920; 10078pp; English.
XX
CC The invention relates to human nucleic acids (AAI57798-AAI61369) and
CC the encoded polypeptides (AAM38642-AAM42213) with nootropic,
CC immunosuppressant and cytostatic activity. The polynucleotides are useful
CC in gene therapy. A composition containing a polypeptide or polynucleotide
CC of the invention may be used to treat diseases of the peripheral nervous
CC system, such as peripheral nervous injuries, peripheral neuropathy and
CC localised neuropathies and central nervous system diseases, such as
CC Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
CC lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
CC utilisation of the activities such as: Immune system suppression,
CC Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic

CC and thrombolytic activity, cancer diagnosis and therapy, drug screening,
 CC assays for receptor activity, arthritis and inflammation, leukaemias and
 CC C.N.S disorders.
 CC Note: The sequence data for this patent did not form part of the printed
 CC specification.
 XX
 SD Sequence 772 AA;

Query Match 100.0%; Score 4037; DB 22; Length 772;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 772; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

QY 1 MRLSSILALLRPALPLILGLSLGCSLSLLRVSWIDGEGEDFCVEAVGERGEPQIPDSFAR 60
   | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 1 mrlssllailrpalplilglslgcsllrvswidgedpceavgergyppmpdsrar 60

QY 61 LDQSDDEDFKPRIVPYRDPNKPYKKVLETRYIQTELGSFERLLVAVLTSRATLSTLAVAV 120
   | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 61 ldgsdedikpri ppyrdpnkpykkvlttryi qtelgsrerllvavltsratlstlavav 120

QY 121 NPTVAHHFPRLLYFTGGFGARAEAGMQVYSHGDEFEAWLMSETLRHLHTHFGADYDWFFI 180
   | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 121 nptvahnfprrllyftggfgarapagmqvyshgderfawimsetlrhlhthfgadydwffi 180

QY 181 MQDDTYVQAPPLAALAGHLSINQDLYLGRAEEFAGAGEQARYCHGGFGYLLSFSLLEFLF 240
   | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 181 mqddtyvqaprlaalaghlsinqdlylgraeeffagageqarychggfgyllsrlrlr 240

QY 241 PHLDGCRGDILSAFDEWLGRCLIDSLGVGCNSQHQQQYRSFELAKNRDPEHEGSSAFL 300
   | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 241 phldgcrgdilsafpdewlgrclidslgvgcnsqhqqqyrsfelaknrdpehegssafl 300

QY 301 SAFAVHEVSEGLTMYFLHKRFSALELERAYSEIEQLQAQIRNLTVLTPEGEAGLSWFWGL 360
   | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 301 safavhqvsegtlmyrlhkrfsalelerayseieqlqaqirnitvltpegeaglsfwvgl 360

QY 361 PAFTEPHSRFEVLGWDYFTEGHTFSCALGAPKCEPLQGASRADVGDALETALEQLNRHYQP 420
   | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 361 paftephsrfevlgwdyfteghtfscadgapkceplqgasradvgdaletaleqlnrhyqp 420

QY 421 RLRFQKQQLLINGYRRFDPARGMEYTLDDILLECVTGRGHRRALARVSLRLSRVEILPM 480
   | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 421 rlrfqkqqlllngyrrfdpargmeytldillecvtgrghrralarvslrlsrveilpm 480

QY 481 PYVTEATRQQLVPLLVAAEAAAAPAFLEAFAANVLEPREHALLTLLLVYGPREGGRGAPD 540
   | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 481 pyvteatrqqlvpllvaaeaaaapafleafaanvleprehalltlllvygppreggrgapd 540

QY 541 PFLGVKAAAAELEKRYEGTFLAWLAVRAEASQYRLMDVVSKKHFEVDLFFLTWVTRPG 600
   | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 541 pflgvkaaaalekryegtflawlavraeapsqyrlmdvvskkhpvdtlffltwvtrpg 600

QY 601 PEVLNRCRMNAISGWQAFPPVHFQEEFNPAISPPQSPGAGPDPPSPPGADPSRGAPI 660
   | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 601 pevlnrcrmnaisgwqafppvhfgeefnpspsppgagpdppspgpadpsrgapi 660
  
```

27 661 GGFETRQASAEQCEYNALYLAPARLAGRLAQCEEEERALEGLEWMLVFEPESGLHLFRAY 720
 10 661 ggfrdqasaeqcyndylnahrlagelaggeeealeglewmdvfrfsgllfray 720
 Q7 721 EPGLVQKFSLRDCSPRLSEELYHRCPLSNLEGLGGRAQLAMALFEQEQA NST 772
 10 721 epglvqkfslrdesprlseelyhrcplsnleaglqgraglamalfeqeqanst 772

RESULT 2

AAE80269

ID AAE80269 standard; Protein; 772 AA.

XX

AL AAE80269;

XX

LT 24-APR-2001 (first entry)

XX

FE Human PEO339 protein.

XX

FW Human; FRO; dermatological; antipsoriatic; cytostatic; antiinflammatory;
 FW antiparkinsonian neurotropic; neuroprotective; vulnerary; cardiant;
 FW antiangiogenic; vasotropic; antiasthmatic; antirheumatic; cancer;
 FW antiarthritic; antiinfertility; antidiabetic; antiviral; diabetes;
 FW ophthalmological; gene therapy; skin disease; gastrointestinal disorder;
 FW ischaemia; inflammation.

XX

IS Homo sapiens.

XX

EN WC200104311-A1.

XX

ED 18-JAN-2001.

XX

FE 22-FEB-2000; 2000WC-US04414.

XX

PF 07-JUL-1999; 99US-0143048.
 PF 16-JUL-1999; 99US-0145698.
 PF 18-JUL-1999; 99US-0146222.
 PF 08-SEP-1999; 99WD-US20594.
 PF 13-SEP-1999; 99WI-US20944.
 PF 15-SEP-1999; 99WD-US21090.
 PF 15-SEP-1999; 99WI-US21547.
 PF 05-OCT-1999; 99WD-US23089.
 PF 29-NOV-1999; 99WI-US28214.
 PF 30-NOV-1999; 99WI-US28313.
 PF 16-DEC-1999; 99WD-US30095.
 PF 20-DEC-1999; 99WI-US30911.
 PF 20-DEC-1999; 99WD-US30999.
 PF 05-JAN-2000; 99WD-US00219.

XX

PA GENEETH - GENENTECH INC.

XX

PI Ashkenazi AJ, Botstein D, Desnoyers L, Eaton DL, Ferrara N;
 PI Filvaroff E, Feng S, Gao W, Gerber H, Gerritsen ME, Goddard A;
 PI Godowski PJ, Grimaldi CJ, Gurney AL, Hillan KJ, Kljavin IJ;
 PI Mather JP, Pan J, Pasni NF, Roy MA, Stewart TA, Tumas D;
 PI Williams PM, Wood WI;

XX

ID AAI559277; SEQ ID NO 1140.
 AC AAI559277
 DT 21-OCT-2001 first entry
 DE Human polynucleotide SEQ ID NO 1140.
 KW Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer;
 KW peripheral nervous system; neuropathy; central nervous system; CNS;
 KW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
 KW amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
 KW chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
 KW leukaemia; OS.
 OS Homo sapiens.
 XX
 PN WC200153312 A1.
 XX
 PD 26-JUL-2001
 XX
 PF 26-DEC-2000; 2000WO-US34263.
 XX
 FR 21-JAN-2000; 2000US-0488725.
 FR 25-APR-2000; 2000US-0552317.
 FR 09-JUL-2000; 2000US-0598042.
 FR 19-JUL-2000; 2000US-0620312.
 FR 03-AUG-2000; 2000US-0653450.
 FR 14-SEP-2000; 2000US 0662191.
 FR 19-OCT-2000; 2000US-0693036.
 FR 29-NOV-2000; 2000US-0727344
 XX
 FA (HYSEQ) HYSEQ INC.
 XX
 FI Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;
 FI Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J;
 FI Zhao QA, Zhou P, Goodrich R, Drmanac RT;
 XX
 DR WPI: 2001-442253/47.
 DR P-ESDB; AAM39781.
 XX
 FT Novel nucleic acids and polypeptides, useful for treating disorders
 IT such as central nervous system injuries -
 XX
 FS Claim 1; SEQ ID NO 1140, 10078pp; English.
 XX
 CC The invention relates to human nucleic acids (AAI57798-AAI61369) and
 CC the encoded polypeptides (AAM38642-AAM42213) with nootropic,
 CC immunosuppressant and cytostatic activity. The polynucleotides are useful
 CC in gene therapy. A composition containing a polypeptide or polynucleotide
 CC of the invention may be used to treat diseases of the peripheral nervous
 CC system, such as peripheral nervous injuries, peripheral neuropathy and
 CC localised neuropathies and central nervous system diseases, such as
 CC Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
 CC lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
 CC utilisation of the activities such as: immune system suppression,
 CC Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
 CC and thrombolytic activity, cancer diagnosis and therapy, drug screening,
 CC assays for receptor activity, arthritis and inflammation, leukaemias and
 CC CNS disorders.
 CC Note The sequence data for this patent did not form part of the printed
 CC specification.
 XX
 HQ Sequence 2710 EP; 506 A; 621 C; 824 G; 559 T; 0 other;

Query Match 96.5%; Score 2692; DB 22; Length 2710;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 2692; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

96 ggggggttagttccgacacattcacagttgaagagcagggcagaaggagttgtgaagacagg 157

DL 7 gggggttagttaggagacattacaggttagagttcagggagagagagaggttggtagagacagg 66
 QY 156 aaatatttttggggaatgctgggttcctggaagcagggggccttgctctgtctttgggctc 117
 Db 67 aaatatttttggggaatgctggttcctggaagcagggggccttgctctgtctttgggctc 126
 QY 216 attgacccacaggttctctgggttaaaactgaaagcctactactggcctgggtggccatcaat 277
 Db 127 attgacccacaggttctctgggttaaaactgaaagcctactactggcctgggtggccatcaat 186
 QY 278 ccattgatccttgaggctgtgcccctggggcaccacactggcagggcctaccacatgcg 337
 Db 187 ccattgatccttgaggctgtgcccctggggcaccacactggcagggcctaccacatgcg 246
 QY 336 actgagctcctgttggtctgtgctggccacagcgttccctcatcttagggctgtctct 397
 Db 247 actgagctcctgttggtctgtgctggccacagcgttccctcatcttagggctgtctct 306
 QY 398 ggggtgcagcctgagcctcctgagggtttcctggatccagggggagggagaaatccctg 457
 Db 307 ggggtgcagcctgagcctcctgagggtttcctggatccagggggagggagaaatccctg 366
 QY 458 tctcgaggctgttaggggagcagggagggccacagaatccagattcgagagctcggctaga 517
 Db 367 tctcgaggctgttaggggagcagggagggccacagaatccagattcgagagctcggctaga 426
 QY 518 ccaaaagtgatgaagacttcaaaaccccggttctcctactacagggaccccaacaagcc 577
 Db 427 ccaaaagtgatgaagacttcaaaaccccggttctcctactacagggaccccaacaagcc 486
 QY 578 ctacaagaagggtgctcaggactcgggtacatccagacagagctgggctcccgtagcggtt 637
 Db 487 ctacaagaagggtgctcaggactcgggtacatccagacagagctgggctcccgtagcggtt 546
 QY 638 gctgggtgggtgtctctgacctcagagctactgtccactttggccgtggctgtgaaccg 697
 Db 547 gctgggtgggtgtctctgacctcagagctactgtccactttggccgtggctgtgaaccg 606
 QY 698 tacgggtggcccatcacttccctcggttactctacttcaactgggcagcggggggcccgggc 757
 Db 607 tacgggtggcccatcacttccctcggttactctacttcaactgggcagcggggggcccgggc 666
 QY 753 tccagcagggtatgcagggtgtgtctcatggggatgagcggcccgctgggtcatgtcaga 817
 Db 667 tccagcagggtatgcagggtgtgtctcatggggatgagcggcccgctgggtcatgtcaga 726
 QY 818 gacctgcccacaccttcacacacactttggggcagactacgactgggttcttcatcatgca 877
 Db 727 gacctgcccacaccttcacacacactttggggcagactacgactgggttcttcatcatgca 786
 QY 878 ggatgacacatatgtgcagggcccccgcctgggagcccttgcctggccacacacagcatcaa 937
 Db 787 ggatgacacatatgtgcagggcccccgcctgggagcccttgcctggccacacacagcatcaa 846
 QY 938 ccaagacctgtacttagggcggggcagaggagttcattgggcagggcagcagggccggta 997
 Db 847 ccaagacctgtacttagggcggggcagaggagttcattgggcagggcagcagggccggta 906
 QY 998 ctgtcatgggggctttgggtacctgtttgtcaaggagtctctgttctgtctggggccaca 1057
 Db 907 ctgtcatgggggctttgggtacctgtttgtcaaggagtctctgttctgtctggggccaca 966
 QY 1058 tctggatgggtgcccaggagacattctcagtgccgtcctgacagagtggttggacgtg 1117
 Db 967 tctggatgggtgcccaggagacattctcagtgccgtcctgacagagtggttggacgtg 1026

Qy 1116 cctcattgactctctctgggggtgggtatggtcacaagcagcaggggagcaggtatcgctc 1177
 Db 1017 cctcattgactctctctgggggtgggtatggtcacaagcagcaggggagcaggtatcgctc 1086

Qy 1176 atttgaaactggcctaaaaatagggacccctgagaaggaaggagagctcggtcttctgagtgc 1237
 Db 1067 atttgaaactggcctaaaaatagggacccctgagaaggaaggagagctcggtcttctgagtgc 1146

Qy 1238 cttcgccgtgacccctgtctccgaaggtaccctcatgtacggctccacaaacgcttcag 1297
 Db 1147 cttcgccgtgacccctgtctccgaaggtaccctcatgtacggctccacaaacgcttcag 1206

Qy 1298 cgcctctggaggtggagcgggcttacagtgaataagaacaactgcaggtcagatcggaa 1357
 Db 1207 cgcctctggaggtggagcgggcttacagtgaataagaacaactgcaggtcagatcggaa 1266

Qy 1358 cctgaccgtgctgaccccggaaggggagggcagggctgagctggcccggtgggctccctgc 1417
 Db 1267 cctgaccgtgctgaccccggaaggggagggcagggctgagctggcccggtgggctccctgc 1326

Qy 1418 tcccttcacacacacactctcgtcttgaggtgctgggctgggaactacttacagagcagaa 1477
 Db 1327 tcccttcacacacacactctcgtcttgaggtgctgggctgggaactacttacagagcagaa 1386

Qy 1478 caccttctcctgtgcagatggggctcccaagtgcacactacagggggctagcagggcgga 1537
 Db 1387 caccttctcctgtgcagatggggctcccaagtgcacactacagggggctagcagggcgga 1446

Qy 1538 cgtgggtgatcggtggagactgccctggagcagctcaatcggcgctatcagcccgct 1597
 Db 1447 cgtgggtgatcggtggagactgccctggagcagctcaatcggcgctatcagcccgct 1506

Qy 1598 gcgcttcacagaagcagcagctgctcaacggctatcggcgcttcgaccagcaggggcat 1657
 Db 1507 gcgcttcacagaagcagcagctgctcaacggctatcggcgcttcgaccagcaggggcat 1566

Qy 1658 ggagtaaacctggacatgctgttggaatgtgtgacacagcgtgggcacggggcgct 1717
 Db 1567 ggagtaaacctggacatgctgttggaatgtgtgacacagcgtgggcacggggcgct 1626

Qy 1718 ggctcgaagggtcagcctgctgcggccactgagccgggtggaaatcctacctatgccta 1777
 Db 1627 ggctcgaagggtcagcctgctgcggccactgagccgggtggaaatcctacctatgccta 1686

Qy 1778 tgtcactgagggcaccagagtgcajctgggtgctgccactcctgggtggtgaagctgctgc 1837
 Db 1687 tgtcactgagggcaccagagtgcajctgggtgctgccactcctgggtggtgaagctgctgc 1746

Qy 1838 agccctggctttcttcagagcgtttgcagccaatgtctcggagccacagagaacatgcatt 1897
 Db 1747 agccctggctttcttcagagcgtttgcagccaatgtctcggagccacagagaacatgcatt 1806

Qy 1898 gctcactctgttctgtggtctacgggcacagagaaggtggcctggagctccagacatt 1957
 Db 1807 gctcactctgttctgtggtctacgggcacagagaaggtggcctggagctccagacatt 1866

Qy 1958 tcttgggggtgaaggtgcagcagcaggttagagcagcaggtacccctgggacgaggtggc 2017
 Db 1867 tcttgggggtgaaggtgcagcagcaggttagagcagcaggtacccctgggacgaggtggc 1926

Qy 2018 ctggctcgtgtgtgcagcagagggccctctccaggtgcgactcatggagctggtctcgaa 2077
 Db 1927 ctggctcgtgtgtgcagcagagggccctctccaggtgcgactcatggagctggtctcgaa 1986

Qy 2078 gaagcaccctgtggacactctctcttctccttaccaccgtgtggacaaggcctgggcccga 2137

DB 1967 gaagcaacatgaggatacttcttttcccttaaacacgttggaacaaggcctggggccga 2046

QY 2136 agtcctcaaccgctgtgcgaatgaatgatctcttggctgggaaggccttctttccagtcca 2197

Db 2047 agtcctcaaccgctgtgcgaatgaatgccatctcttggctgggaaggccttctttccagtcca 2106

QY 2198 ttttcaggaggttcaatcctgcacctgtcaccaacagagatcacccccaggggccccgggggg 2257

Db 2107 ttttcaggaggttcaatcctgcacctgtcaccaacagagatcacccccaggggccccgggggg 2166

QY 2258 tggccctgacccccctcccctcctgggtgctgacctctccgggggggtcctatataggggg 2317

Db 2147 tggccctgacccccctcccctcctgggtgctgacctctccgggggggtcctatataggggg 2226

QY 2318 gagatttgaccggcaggcttctcgaggagggtgcttctacaacgctgactacctggcggc 2377

Db 2227 gagatttgaccggcaggcttctcgaggagggtgcttctacaacgctgactacctggcggc 2286

QY 2378 ccgagcccggtggcagggtgaactggcaggccaggaagaggaggaagccctggaggggct 2437

Db 2187 ccgagcccggtggcagggtgaactggcaggccaggaagaggaggaagccctggaggggct 2346

QY 2438 ggaggtgatggatgttttccctccggttctcagggttccacctcttttggggcgttagagcc 2497

Db 2347 ggaggtgatggatgttttccctccggttctcagggttccacctcttttggggcgttagagcc 2406

QY 2498 agggctgggtgcagaagttctccctgcgagactgcagccacaggctcagtgaaagaactcta 2557

Db 2407 agggctgggtgcagaagttctccctgcgagactgcagccacaggctcagtgaaagaactcta 2466

QY 2558 ccaccgctgcgcctcagcaacctggaggggctagggggccgtgcccagctggctatggc 2617

Db 2467 ccaccgctgcgcctcagcaacctggaggggctagggggccgtgcccagctggctatggc 2526

QY 2618 tctcttttgagcaggagcaggccaatagcacttagcccgctgggggcccctaacctcatta 2677

Db 2527 tctcttttgagcaggagcaggccaatagcacttagcccgctgggggcccctaacctcatta 2586

QY 2678 cttttctctttgtctgcctcagccccaggaagggcaaggcaagatgggtggacagatagaga 2737

Db 2587 cttttctctttgtctgcctcagccccaggaagggcaaggcaagatgggtggacagatagaga 2646

QY 2738 attgttgctgtattttttaaatatgaaaaatgtatttaaactgtcttctgcc 2789

Db 2647 attgttgctgtattttttaaatatgaaaaatgtatttaaactgtcttctgcc 2698